Mr Jin Yang

Tenaya Therapeutics, South San Francisco (United States of America)

Membership: HFA Member

Contributor content

$HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction$

Presentation

HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction

$HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction$

Presentation

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

Explore sponsored resources

Mr Jin Yang

Contributor content

HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction

HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction

ESC 365 is supported by